Keri L. Schaubert, Ph.D.


Keri concentrates her practice on complex patent cases for clients in the pharmaceutical and biotechnology industries. She is a registered patent attorney and represents companies in Hatch-Waxman and biosimilar litigation. Keri handles all aspects of patent cases including pre-suit investigations, fact and expert discovery, dispositive motions, and trials. She also has experience in IPR matters at the PTAB on behalf of both patent owners and challengers.

Prior to attending law school, Keri received her Ph.D. in immunology from Wayne State University School of Medicine where, as a part of her doctoral research, she studied human CD8+ T cell responses to HIV epitopes and mimotopes thereof. Keri then completed a postdoctoral fellowship at the University of Michigan where she examined the role of transforming growth factor-β (TGF-β) in natural killer (NK) cell maturation. Keri has been published in numerous immunology journals.

Keri serves as co-chair of the firm's Members' Committee. She is a graduate of Loyola University Chicago School of Law, and earned a bachelor’s degree in biology and anthropology from the University of Michigan.



Fed. Circ. Won't Revive Vanda's Sleep Disorder Patent Claims

May 10, 2023

Cozen O'Connor successfully represented Apotex in a patent dispute with Vanda Pharmaceuticals over the sleep disorder drug Hetlioz.

Fed. Circ. Won't Bar Generic Sleep Meds Amid Vanda Appeal

January 03, 2023

Cozen O'Connor successfully represented Apotex at the U.S. Court of Appeals for the Federal Circuit in securing a denial of Vanda Pharmaceuticals' bid to seek an injunction pending an appeal of Apotex's and Teva's victory in the District of Delaware.

Teva, Apotex Win Ax Of Patents In Sleep Drug Suit

December 13, 2022

Cozen O’Connor scored a major win for Apotex Inc. and Apotex Corp. in federal court in Delaware.

Fintiv Rule Challenges Face Long Odds After Fed. Circ. Ruling

March 16, 2021

Keri Schaubert was quoted in Law360 discussing how technology companies and generic-drug makers have said the policy, known as the NHK-Fintiv rule after the PTAB rulings that established it, unfairly restricts the ability to seek inter partes review of patents under the America Invents Act.

Virus Delays, Few Approvals Dry Up Generic Drug Lawsuits in 2020

September 09, 2020

Keri Schaubert was quoted in Bloomberg Law discussing drug patent lawsuits that took a 21% dive from this time last year, a “perfect storm” that traces back to 2016 when the FDA only approved a handful of new drugs.

Cozen O’Connor Promotes 20 to Membership

April 08, 2020

Cozen O'Connor is pleased to recognize 20 attorneys with the promotion to member.


The PTAB Puts Hatch-Waxman Defendants on Notice: File IPRs Early or Risk Fintiv Discretionary Denial [IPWatchdog]

October 29, 2020

Blake Coblentz, Aaron Lukas, and Keri Schaubert wrote about the Patent Trial and Appeal Board (PTAB) denying the institution of Mylan Labs Ltd.’s petition for IPR of U.S. Patent No. 9,439,906 (“the ’906 patent”) in IPR2020-00440.

Exercising discretion [Intellectual Property Magazine]

July 09, 2020

Keri Schaubert and Aaron Lukas consider a precedential PTAB order outlining six factors in exercising discretion to deny institution of IPR proceedings.

PTAB Settlement Disclosure Timing Crucial After DTN Ruling [Law 360]

July 07, 2020

Aaron Lukas and Keri Schaubert wrote an article on the Patent Trial and Appeal Board decision in DTN LLC v. Farms Technology LLC.

The Trans-Pacific Partnership and Its Effect On Biosimilars [Inside Counsel]

November 23, 2015

Aaron Lukas and Keri Schaubert, associates of Cozen O’Connor’s IP group, discuss the effect that the Trans-Pacific Partnership will have on the biopharmaceutical and biosimilar industry.

Events & Seminars

Upcoming Events

To Dance or Not to Dance? Updated Venue Selection Matrices for a Maturing Biosimilar Industry

June 21, 2024 - New York, NY

Keri Schaubert will present “To Dance or Not to Dance? Updated Venue Selection Matrices for a Maturing Biosimilar Industry” at the American Conference Institute’s 15th Summit on Biosimilars & Innovator Biologics.

Past Events


  • Loyola University Chicago School of Law, J.D., 2013
  • Wayne State University of Medicine, Ph.D., 2006
  • University of Michigan, B.S., 2000
  • Illinois
  • United States Patent and Trademark Office
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. Court of Appeals for the Fifth Circuit